DelveInsight’s, “Coronary Artery Disease Pipeline Insight 2023” report provides comprehensive insights about 30+ Coronary Artery Disease companies and 30+ pipeline drugs in Coronary Artery Disease pipeline landscape. It covers the Coronary Artery Disease pipeline drug profiles, including Coronary Artery Disease clinical trials and nonclinical stage products. Coronary Artery Disease pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Coronary Artery Disease Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Coronary Artery Disease NDA approvals (if any), and product development activities comprising the technology, Coronary Artery Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Coronary Artery Disease Pipeline treatment landscape of the report, click here @ Coronary Artery Disease Pipeline Outlook

 

Key Takeaways from the Coronary Artery Disease Pipeline Report

• DelveInsight’s Coronary Artery Disease Pipeline analysis depicts a robust space with 30+ active players working to develop 30+ pipeline treatment therapies.
• The leading Coronary Artery Disease Companies are working in the market include Idorsia Pharmaceuticals, AstraZeneca, Sinotau Pharmaceuticals, XyloCor Therapeutics, AdvanceCor, Sinotau Pharmaceuticals, GE Healthcare, Honya Medical Inc, Novartis Pharmaceuticals, Merck, Bayer, Daiichi Sankyo Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Kastle Therapeutics LLC, Ionis Pharmaceuticals Inc, and others
• Emerging Coronary Artery Disease Pipeline Therapies in the various stages of development include Moxifloxacin, Vericiguat (BAY1021189), mipomersen sodium, Rivaroxaban, clopidogrel, prasugrel, Ticagrelor Maintenance Dose, Isosorbide mononitrate (ISMN), and others
• Selatogrel, is a small molecule being developed by Idorsia Pharmaceuticals. It acts as a P2Y12 receptor antagonist. Currently, the drug is being studied in Phase II stage of Clinical trial evaluation for the treatment of Coronary artery disease.
• Atuliflapon (formerly AZD 5718) is an orally available, small molecule, 5-lipoxygenase activating protein inhibitor, being developed by AstraZeneca. Currently, the drug is being studied in Phase II stage of clinical trial evaluation for the treatment of Coronary artery disease.
• XTR003 is a PET imaging radiopharmaceutical agent used to trace myocardial fatty acid metabolism. XTR003 is a modified fatty acid that enters the myocytes and passes through mitochondrial membrane by the same process as the natural existing fatty acids and then undergoes partial β-oxidation before being trapped in the mitochondria. In preclinical study XTR003 showed high myocardial uptake and retention. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Coronary Artery Disease.

 

Coronary Artery Disease Overview

Coronary artery disease (CAD) is the most common type of heart disease in the United States. It is sometimes called coronary heart disease or ischemic heart disease. Coronary Artery Disease is caused by plaque buildup in the walls of the arteries that supply blood to the heart (called coronary arteries) and other parts of the body.

 

For further information, refer to the detailed Coronary Artery Disease Unmet Needs, Coronary Artery Disease Market Drivers, and Market Barriers, click here for Coronary Artery Disease Ongoing Clinical Trial Analysis

 

Coronary Artery Disease Emerging Drugs Profile

• Selatogrel: Idorsia Pharmaceuticals
• Atuliflapon: AstraZeneca
• XTR 003: Sinotau Pharmaceuticals

 

Coronary Artery Disease Pipeline Therapeutics Assessment

There are approx. 30+ Coronary Artery Disease Coronary Artery Disease companies which are developing the therapies for Coronary Artery Disease. The Coronary Artery Disease companies which have their Coronary Artery Disease drug candidates in the most advanced stage, i.e. Phase II include, Idorsia Pharmaceuticals.

 

Request a sample and discover the recent advances in Coronary Artery Disease Ongoing Clinical Trial Analysis and Medications, click here @ Coronary Artery Disease Treatment Landscape

 

Coronary Artery Disease Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Coronary Artery Disease Therapeutics Market include-

Idorsia Pharmaceuticals, AstraZeneca, Sinotau Pharmaceuticals, XyloCor Therapeutics, AdvanceCor, Sinotau Pharmaceuticals, GE Healthcare, Honya Medical Inc, Novartis Pharmaceuticals, Merck, Bayer, Daiichi Sankyo Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Kastle Therapeutics LLC, Ionis Pharmaceuticals Inc, and others

 

Dive deep into rich insights for drugs for Coronary Artery Disease Pipeline, click here @ Coronary Artery Disease Unmet Needs and Analyst Views

 

Scope of the Coronary Artery Disease Pipeline Report

• Coverage- Global
• Coronary Artery Disease Companies- Idorsia Pharmaceuticals, AstraZeneca, Sinotau Pharmaceuticals, XyloCor Therapeutics, AdvanceCor, Sinotau Pharmaceuticals, GE Healthcare, Honya Medical Inc, Novartis Pharmaceuticals, Merck, Bayer, Daiichi Sankyo Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Kastle Therapeutics LLC, Ionis Pharmaceuticals Inc, and others
• Coronary Artery Disease Therapies- Moxifloxacin, Vericiguat (BAY1021189), mipomersen sodium, Rivaroxaban, clopidogrel, prasugrel, Ticagrelor Maintenance Dose, Isosorbide mononitrate (ISMN), and others
• Coronary Artery Disease Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Coronary Artery Disease Merger and acquisitions, Coronary Artery Disease Licensing Activities @ Coronary Artery Disease Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Coronary Artery Disease Executive Summary
3. Coronary Artery Disease: Overview
4. Coronary Artery Disease Pipeline Therapeutics
5. Coronary Artery Disease Therapeutic Assessment
6. Coronary Artery Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Selatogrel: Idorsia Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. XTR 003: Sinotau Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Coronary Artery Disease Products
20. Coronary Artery Disease Key Companies
21. Coronary Artery Disease Key Products
22. Coronary Artery Disease- Unmet Needs
23. Coronary Artery Disease- Market Drivers and Barriers
24. Coronary Artery Disease- Future Perspectives and Conclusion
25. Coronary Artery Disease Analyst Views
26. Coronary Artery Disease Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services